Y van der Does1, M Limper2, K E Jie3, S C E Schuit4, H Jansen5, N Pernot3, J van Rosmalen6, M J Poley7, C Ramakers8, P Patka9, E C M van Gorp10, P P M Rood9. 1. Department of Emergency Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands. Electronic address: y.vanderdoes@erasmusmc.nl. 2. Department of Rheumatology and Clinical Immunology, University Medical Centre, Utrecht University, Utrecht, the Netherlands. 3. Department of Emergency Medicine, Jeroen Bosch Ziekenhuis, Den Bosch, The Netherlands. 4. Department of Emergency Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands. 5. Department of Internal Medicine, Jeroen Bosch Ziekenhuis, Den Bosch, The Netherlands. 6. Department of Biostatistics, Erasmus University Medical Center, Rotterdam, The Netherlands. 7. Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands; Intensive Care and Department of Paediatric Surgery, Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, The Netherlands. 8. Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands. 9. Department of Emergency Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands. 10. Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Viroscience, Erasmus University Medical Center, Rotterdam, The Netherlands.
Abstract
OBJECTIVES: Overuse of broad-spectrum antibiotics in emergency departments (EDs) results in antibiotic resistance. We determined whether procalcitonin (PCT) -guided therapy can be used to reduce antibiotic regimens in EDs by investigating efficacy, safety and accuracy. METHODS: This was a non-inferiority multicentre randomized clinical trial, performed in two Dutch hospitals. Adult patients with fever ≥38.2°C (100.8°F) in triage were randomized between standard diagnostic workup (control group) and PCT-guided therapy, defined as standard workup with the addition of one single PCT measurement. The treatment algorithm encouraged withholding antibiotic regimens with PCT <0.5 μg/L, and starting antibiotic regimens at PCT ≥0.5 μg/L. Exclusion criteria were immunocompromised conditions, pregnancy, moribund patients, patients <72 h after surgery or requiring primary surgical intervention. Primary outcomes were efficacy, defined as number of prescribed antibiotic regimens; safety, defined as combined safety end point consisting of 30 days mortality, intensive-care unit admission, ED return visit within 2 weeks; accuracy, defined as sensitivity, specificity and area-under-the-curve (AUC) of PCT for bacterial infections. Non-inferiority margin for safety outcome was 7.5%. RESULTS:Between August 2014 and January 2017, 551 individuals were included. In the PCT-guided group (n = 275) 200 (73%) patients were prescribed antibiotic regimens, in the control group (n = 276) 212 (77%) patients were prescribed antibiotics (p 0.28). There was no significant difference in combined safety end point between the PCT-guided group, 29 (11%), and control group, 46 (16%) (p 0.16), with a non-inferiority margin of 0.46% (n = 526). AUC for confirmed bacterial infections for PCT was 0.681 (95% CI 0.633-0.730), and for CRP was 0.619 (95% CI 0.569-0.669). CONCLUSIONS:PCT-guided therapy was non-inferior in terms of safety, but did not reduce prescription of antibiotic regimens in an ED population with fever. In this heterogeneous population, the accuracy of PCT in diagnosing bacterial infections was poor. TRIAL REGISTRATION IN NETHERLANDS TRIAL REGISTER: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=4949.
RCT Entities:
OBJECTIVES: Overuse of broad-spectrum antibiotics in emergency departments (EDs) results in antibiotic resistance. We determined whether procalcitonin (PCT) -guided therapy can be used to reduce antibiotic regimens in EDs by investigating efficacy, safety and accuracy. METHODS: This was a non-inferiority multicentre randomized clinical trial, performed in two Dutch hospitals. Adult patients with fever ≥38.2°C (100.8°F) in triage were randomized between standard diagnostic workup (control group) and PCT-guided therapy, defined as standard workup with the addition of one single PCT measurement. The treatment algorithm encouraged withholding antibiotic regimens with PCT <0.5 μg/L, and starting antibiotic regimens at PCT ≥0.5 μg/L. Exclusion criteria were immunocompromised conditions, pregnancy, moribund patients, patients <72 h after surgery or requiring primary surgical intervention. Primary outcomes were efficacy, defined as number of prescribed antibiotic regimens; safety, defined as combined safety end point consisting of 30 days mortality, intensive-care unit admission, ED return visit within 2 weeks; accuracy, defined as sensitivity, specificity and area-under-the-curve (AUC) of PCT for bacterial infections. Non-inferiority margin for safety outcome was 7.5%. RESULTS: Between August 2014 and January 2017, 551 individuals were included. In the PCT-guided group (n = 275) 200 (73%) patients were prescribed antibiotic regimens, in the control group (n = 276) 212 (77%) patients were prescribed antibiotics (p 0.28). There was no significant difference in combined safety end point between the PCT-guided group, 29 (11%), and control group, 46 (16%) (p 0.16), with a non-inferiority margin of 0.46% (n = 526). AUC for confirmed bacterial infections for PCT was 0.681 (95% CI 0.633-0.730), and for CRP was 0.619 (95% CI 0.569-0.669). CONCLUSIONS: PCT-guided therapy was non-inferior in terms of safety, but did not reduce prescription of antibiotic regimens in an ED population with fever. In this heterogeneous population, the accuracy of PCT in diagnosing bacterial infections was poor. TRIAL REGISTRATION IN NETHERLANDS TRIAL REGISTER: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=4949.
Authors: Marcello Covino; Alberto Manno; Giuseppe Merra; Benedetta Simeoni; Andrea Piccioni; Luigi Carbone; Evelina Forte; Veronica Ojetti; Francesco Franceschi; Rita Murri Journal: Intern Emerg Med Date: 2019-10-24 Impact factor: 3.397
Authors: Charalampos Pierrakos; Dimitrios Velissaris; Max Bisdorff; John C Marshall; Jean-Louis Vincent Journal: Crit Care Date: 2020-06-05 Impact factor: 9.097
Authors: Kordo Saeed; Darius Cameron Wilson; Frank Bloos; Philipp Schuetz; Yuri van der Does; Olle Melander; Pierre Hausfater; Jacopo M Legramante; Yann-Erick Claessens; Deveendra Amin; Mari Rosenqvist; Graham White; Beat Mueller; Maarten Limper; Carlota Clemente Callejo; Antonella Brandi; Marc-Alexis Macchi; Nicholas Cortes; Alexander Kutz; Peter Patka; María Cecilia Yañez; Sergio Bernardini; Nathalie Beau; Matthew Dryden; Eric C M van Gorp; Marilena Minieri; Louisa Chan; Pleunie P M Rood; Juan Gonzalez Del Castillo Journal: Crit Care Date: 2019-02-08 Impact factor: 9.097
Authors: Kirby Tong-Minh; Iris Welten; Henrik Endeman; Tjebbe Hagenaars; Christian Ramakers; Diederik Gommers; Eric van Gorp; Yuri van der Does Journal: BMC Emerg Med Date: 2021-06-13
Authors: Dayle Sampson; Thomas D Yager; Brian Fox; Laura Shallcross; Leo McHugh; Therese Seldon; Antony Rapisarda; Roslyn A Hendriks; Richard B Brandon; Krupa Navalkar; Nandi Simpson; Sian Stafford; Eliza Gil; Cristina Venturini; Evi Tsaliki; Jennifer Roe; Benjamin Chain; Mahdad Noursadeghi Journal: BMC Med Date: 2020-07-21 Impact factor: 8.775
Authors: Anna Maria Azzini; Romolo Marco Dorizzi; Piersandro Sette; Marta Vecchi; Ilaria Coledan; Elda Righi; Evelina Tacconelli Journal: Ann Transl Med Date: 2020-05
Authors: Jaume Baldirà; Juan Carlos Ruiz-Rodríguez; Darius Cameron Wilson; Adolf Ruiz-Sanmartin; Alejandro Cortes; Luis Chiscano; Roser Ferrer-Costa; Inma Comas; Nieves Larrosa; Anna Fàbrega; Juan José González-López; Ricard Ferrer Journal: Ann Intensive Care Date: 2020-01-15 Impact factor: 6.925